metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-8 CHARACTERIZATION AND EPIDEMIOLOGICAL CHANGES OF PATIENTS WITH HEPATITIS C VI...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
O-8 CHARACTERIZATION AND EPIDEMIOLOGICAL CHANGES OF PATIENTS WITH HEPATITIS C VIRUS TREATED IN THE CHILEAN PUBLIC HEALTH SYSTEM FROM 2016 TO 2021.
Visitas
234
Luis Salazar1, Carlos Valdebenito1, Alejandro Carvajal1, Gonzalo Veloso1, Herman Aguirre1, Gabriel Mezzano2,3
1 Training Program in Adult Gastroenterology, University of Chile, Santiago, Chile
2 Gastroenterology and Liver Transplantation Unit, Hospital del Salvador – University of Chile, Santiago, Chile
3 Center for Digestive Disease Clinic, University of The Andes, Santiago, Chile
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Tablas (1)
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

International studies have described an epidemiological change in patients with the hepatitis C virus (HCV), with greater involvement of young people and risk groups. The reality in Latin America, particularly in Chile, is unknown. This study aimed to epidemiologically characterize HCV patients treated in the Chilean public health system (period 2016-2021) and compare these characteristics in two periods (2016 - 2019 vs. 2020 - 2021).

Materials and Methods

Historical cohort was constructed based on national data and the Hospital del Salvador registry (Santiago, Chile) (n=410). All patients diagnosed with HCV treated in the Chilean public system (2016-2019) and those treated at Hospital del Salvador (2020-2021 period) were included. It was registered: year of diagnosis, age, sex, presence of cirrhosis, HCV genotype, co-infection with hepatitis B virus (HBV) and/or HIV, need for a liver transplant, or intratreatment dead. Both periods were compared using the Mann-Whitney U test or Fisher's exact test, as appropriate.

Results

61.2% of patients were male, with a median age of 57 years. 73.5% presented genotype 1 and 11.6% genotype 4. There was a 19.3% coinfection with HIV. Only 1.4% had therapy failure at 24 weeks and 5.2% of patients underwent liver transplantation. When comparing the periods 2016 – 2019 vs. 2020 – 2021 a reduction in the median age 59 vs 49 (p<0.001) was observed, with a higher proportion of male gender 79.0% vs 51.7% (p<0.001). There is evidence of change in the proportion of the genotypes, with genotype four being the second most frequent after genotype 1. The presence of co-infection with HIV was 49.7% vs. 3.0% (p<0.001) and HBV/HIV 15.5% vs. 0.8% (p<0.001). There was no difference in the percentage of sustained viral response (Table 1).

Conclusions

There is an epidemiological change in HCV patients, which suggests different routes of transmission and the need to refocus screening.

Texto completo

Table 1: Result and comparison of socio-demographic and clinical variables between the periods 2016-2019 and 2020-2021.

  Total (n = 410)  Period 2016-2019 (n = 267)  Period 2020-2021 (n = 143)  p-value 
Age (years), median (p25, p75)  57 (46, 64)  59 (52, 66)  49 (36, 61)  <0.001 
Male, n(%)  251 (61.2%)  138 (51.7%)  113 (79.0%)  <0.001 
Period years, n(%)         
2016  48 (11.7%)   
2017  26 (6.3%)   
2018  183 (44.6%)   
2019  10 (2.4%)   
2020  71 (17.3%)   
2021  72 (17.6%)   
Genotype, n (%)        <0.001 
285 (73.5%)  209 (78.9%)  76 (61.8%)   
7 (1.8%)  4 (1.5%)  3 (2.4%)   
50 (12.9%)  36 (13.6%)  14 (11.4%)   
45 (11.6%)  15 (5.7%)  30 (24.4%)   
3 and 4  1 (0.3%)  1 (0.4%)  0 (0.0%)   
HBV co-infection, n (%)  17 (4.1%)  3 (1.1%)  14 (9.8%)  <0.001 
HIV co-infection, n (%)  79 (19.3%)  8 (3.0%)  71 (49.7%)  <0.001 
HIV-HBV co-infection, n (%)  15 (4.4%)  2 (0.8%)  13 (15.5%)  <0.001 
Cirrhosis, n (%)  214 (54.7%)  183 (68.5%)  31 (25.0%)  <0.001 
Failure at 12 weeks, n (%)  9 (2.8%)  8 (3.8%)  1 (0.9%)  0.17 
Failure at 24 weeks, n (%)  4 (1.4%)  3 (1.5%)  1 (1.3%)  1.00 
Use of rescue therapy, n (%)  139 (35.2%)  256 (95.9%)  0 (0.0%)  <0.001 
Liver transplant, n (%)  21 (5.2%)  20 (7.5%)  1 (0.7%)  0.002 
Kidney transplant, n (%)  1 (0.2%)  1 (0.4%)  0 (0.0%)  >0.999 
Other outcomes, n (%)        0.495 
Therapy failure  12 (3.4%)  10 (4.3%)  2 (1.6%)   
SVR  334 (93.3%)  216 (92.3%)  118 (95.2%)   
Discontinues treatment  5 (1.4%)  4 (1.7%)  1 (0.8%)   
Deads  7 (2.0%)  4 (1.7%)  3 (2.4%)   

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos